Baidu
map

警惕:氨氯地平与这3种他汀的相互作用

2018-03-29 佚名 药品之声

在临床上,氨氯地平与他汀类药物合用非常广泛。许多医生和药师认为氨氯地平较安全,与他汀类降脂药不存在相互作用。但研究证明,氨氯地平与辛伐他汀和洛伐他汀合用时具有明显的相互作用,与阿托伐他汀合用时也可能会发生横纹肌溶解症。

临床上,氨氯地平与他汀类药物合用非常广泛。许多医生和药师认为氨氯地平较安全,与他汀类降脂药不存在相互作用。但研究证明,氨氯地平与辛伐他汀和洛伐他汀合用时具有明显的相互作用,与阿托伐他汀合用时也可能会发生横纹肌溶解症。

一、氨氯地平与辛伐他汀、洛伐他汀合用:他汀的血药浓度升高

氨氯地平为肝药酶CYP3A4抑制药。

辛伐他汀和洛伐他汀,主要经肝药酶CYP3A4途径代谢。当与CYP3A4抑制药合用时,辛伐他汀、洛伐他汀的血药浓度升高,肌病的发生风险增加。



例如,辛伐他汀与氨氯地平片联合使用,辛伐他汀的血浆峰浓度(Cmax)增加43%,药-时曲线下面积(AUC)增加28%,而降脂疗效并没有显着增加。

SKOVBOLLING等报道1例71岁男性在辛伐他汀与氨氯地平联用7天后出现横纹肌严重溶解的病例。

基于大量的病例和回顾性研究:

(1)2011年,美国FDA发出黑框警告,当辛伐他汀与氨氯地平合用时,辛伐他汀日剂量不得超过20mg。

(2)2016年,美国心脏协会(AHA)提醒:当辛伐他汀、洛伐他汀与氨氯地平合用时,辛伐他汀、洛伐他汀的日剂量不要超过20mg。

温馨提示:血脂康胶囊(片)中含有洛伐他汀(≥2.5mg/粒),应格外关注与红霉素、克拉霉素、伊曲康唑、胺碘酮、氨氯地平、贝特类降脂药之间的相互作用。

二、氨氯地平与阿托伐他汀合用:警惕横纹肌溶解症发生风险

阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等。

虽然,在阿托伐他汀的药品说明书中,并未提示氨氯地平与阿托伐他汀合用的风险。但是,日本在过去的3年中,在接受氨氯地平和阿托伐他汀联合治疗的患者中共报告了6例横纹肌溶解症。

因此,2016年1月12日,日本厚生劳动省(MHLW)和药品医疗器械管理局(PMDA)建议:阿托伐他汀钙与氨氯地平的复方制剂说明书中列出暴发性肝炎、粒细胞缺乏症、横纹肌溶解症风险,作为临床显着的不良反应。

他汀类药物的用药交代:

(1)立即报告原因不明的肌肉疼痛、肌肉压痛或肌肉无力,尤其是伴有不适或发热时;定期检测肌酸磷酸激酶水平。

(2)立即报告非正常的疲劳或无力、食欲不振、上腹疼痛、尿色深、皮肤或巩膜黄染,定期检测肝功能。



三、用药案例

患者,男,69岁。诊断:冠心病、PCI术后、心绞痛、高血压病、2型糖尿病

阿司匹林肠溶片100mg,qd,po,硫酸氯吡格雷片75mg,qd,po。辛伐他汀片40mg,qn,po;苯磺酸氨氯地平片2.5mg,qd,po,泮托拉唑肠溶胶囊40mg,qd,po,格列齐特缓释片30mg,qd,po。

用药分析:

(1)辛伐他汀与氨氯地平联用,可使前者血药浓度升高,增加发生肌毒性的风险;瑞舒伐他汀不经过CYP3A4代谢,与氨氯地平不存在相互作用,建议换用瑞舒伐他汀;

(2)该患者高血压伴有糖尿病,ACEI或ARB(如贝那普利,缬沙坦)不仅有较强的降压作用,而且可逆转心室重构,并能改善胰岛素抵抗,是糖尿病合并高血压的首选药物,可考虑替换氨氯地平。

结果:

换用瑞舒伐他汀钙片10mg,qd,po,贝那普利片5mg,qd,po。患者在院期间血压控制良好,未出现肌痛、肌炎等不良反应。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2023-01-28 xiaoyan1028 来自安徽省

    阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-31 ylz8405
  5. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-31 1ddf0692m34(暂无匿称)

    学习了.谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-30 lou.minghong

    这个资料好!收藏!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-30 1dd8c52fm63(暂无匿称)

    了解了解.继续关注

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-30 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-30 121832a9m88暂无昵称

    学习了

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2111911, encodeId=8acd21119110c, content=阿托伐他汀通过CYP3A4代谢,与CYP3A4强抑制药合用时,可引起阿托伐他汀的血药浓度升高。如红霉素、克拉霉素、伊曲康唑、HIV蛋白酶抑制剂(利托那韦、沙奎那韦等)等, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ5sZvgWg1pBRCs01YgtiaKOTqsCYpwB10OEmxs01VY4ECBsjeMGbmFTEO0pXyEMzibViaVUFseXDXeQ/132, createdBy=8bf35206165, createdName=xiaoyan1028, createdTime=Sat Jan 28 21:17:42 CST 2023, time=2023-01-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1909238, encodeId=199319092382f, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Jun 23 12:44:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341281, encodeId=0e771341281c1, content=<a href='/topic/show?id=20bf640515d' target=_blank style='color:#2F92EE;'>#氨氯地平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64051, encryptionId=20bf640515d, topicName=氨氯地平)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471580, encodeId=ade514e158099, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sat Mar 31 14:44:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301489, encodeId=d26a30148958, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 31 13:18:24 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301122, encodeId=3778301122ef, content=这个资料好!收藏!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Fri Mar 30 08:10:27 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301118, encodeId=21c1301118dd, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Mar 30 07:49:49 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301027, encodeId=180030102e0c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Mar 30 06:08:10 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301016, encodeId=5fda301016fb, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Mar 30 06:01:31 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301010, encodeId=cbcc301010a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Fri Mar 30 05:55:29 CST 2018, time=2018-03-30, status=1, ipAttribution=)]
    2018-03-30 青山颖钰

    学习了

    0

相关资讯

ASH 2014:与氨氯地平的降压药组合 奈必洛尔优于美托洛尔

美国高血压学会年会(ASH 2014)公布的一项研究表明,与氨氯地平/美托洛尔(A/M)相比,氨氯地平/奈必洛尔(A/N)在降低24小时动态血压(ABPM)方面具有优势,并且致患者足踝部水肿程度较轻。此项研究共纳入41例高血压成人患者,并启动4周氨氯地平(10 mg/d)单药治疗。随后添加4周小剂量奈必洛尔或美托洛尔治疗,并在后续4周强制滴定至大剂量奈必洛尔(20 mg/d)或美托洛尔(100 m

他们想从“4毛钱处方”中看到什么?

原标题《“4毛钱药方”治愈了谁?》 13日,一则#医生开4毛钱药#挺进微博热搜榜,从网友开骂只会开贵药的医生缺德,到医生大V们的无力吐槽,舆情在一天内现逆转。 事件还原医生开4毛钱药方治愈患者据10月12日华商报报道,西安刘女士的爱人王先生患有高血压,一直坚持服药。国庆出游回来,王先生的血压一直降不下去,吃降压药也不管用。10月7日晚11点多,他们到五二一医院挂急诊,医生只开了

钙拮抗剂为基础的联合降压效优

  发表于2012年第3期《中华高血压杂志》上研究表明,以钙拮抗剂氨氯地平为基础,联合替米沙坦或复方阿米洛利均能够降低高血压患者中心动脉压(CAP)、增强指数和改善大动脉顺应性,其中氨氯地平联合替米沙坦改善动脉弹性更明显,并且随着治疗时间的延长,效果更佳。   研究旨在探讨氨氯地平联合复方阿米洛利或联合替米沙坦对CAP和脉搏波传导速度(PWV)的影响。研究者们采用随机抽样方法选取2008-03-

Lancet:不同体重人群的利尿剂降压治疗存在差异

     美国学者的一项研究表明,体重正常和肥胖患者的高血压可能经由不同机制介导。基于噻嗪类的治疗对体重正常患者的心血管保护作用可能逊色于肥胖患者,但基于氨氯地平的治疗则可在不同体质指数(BMI)患者中发挥相同效应。论文于2012年12月5日在线发表于《柳叶刀》(Lancet)。   此项研究基于BMI将ACCOMPLISH试验受试人群分为肥胖(BMI ≥30,n=570

Am J Kidney Dis:肾移植受者:氯噻酮VS氨氯地平哪个效果更好?

2017年6月,发表在《Am J Kidney Dis》的一项由荷兰科学家进行的研究,得出了氯噻酮与氨氯地平对于他克莫司治疗的肾移植受者降压等效的结论。

Neurology:氨氯地平反应性三叉神经痛——病例报道

氨氯地平减轻三叉神经痛的机制:电压门控钙通道能够减轻血管迂曲,以及N型通道(交感调节/镇痛作用)的作用。

Baidu
map
Baidu
map
Baidu
map